It's never been associated with injectible PPS. There are no examples whatsoever, and that's probably due to the treatment doses used in subcutaneous injection being miniscule compared to the cumulative long-term use of oral administration e.g. Elmiron for IC.
Despite that, PAR have previously mentioned that they will be monitoring for this in their Phase III trials.
It's never been associated with injectible PPS. There are no...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $101.6K | 424.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144266 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 18540 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |